Healthcare, Pharma & Life Sciences

Beta Bionics Faces Securities Fraud Suit Over iLet Pump Disclosures

Los Angeles – September 11, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between September 11, 2026 and September 11, 2026, with a lead plaintiff filing deadline set for September 11, 2026.

Complaint alleges Beta Bionics downplayed FDA findings on its iLet insulin pump

The complaint centers on the iLet Bionic Pancreas insulin pump, Beta Bionics' sole commercialized product. After the company disclosed that the FDA had issued a Form 483 following a manufacturing facility inspection, defendants allegedly told investors the agency's observations were limited to complaint-reporting criteria and did not reflect underlying device problems.

Schall, Brown & Schwartz Files Securities Fraud Suit Against Beta Bionics

Los Angeles – – September 11, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.

Class period spans July 2025 to February 2026 amid disputed FDA findings

The class covers purchasers of Beta Bionics common stock between September 11, 2026 and September 11, 2026. Investors face a September 11, 2026 deadline to seek appointment as lead plaintiff.

Genesis Wins AFR Sustainability Award for Algae Livestock Supplement

Image
Genesis Wins AFR Sustainability Award for Algae Livestock Supplement

Melbourne – September 11, 2026 -- Australian microalgae company Genesis has won the Agriculture & Environment category at The Australian Financial Review Sustainability Leaders 2026 Awards for a Chlorella-based livestock supplement priced at roughly 20 cents per animal per day, against approximately $2 for some dried alternatives.

Wet-processed Chlorella cuts supplement costs to a fraction of dried competitors

Genesis cultivates Chlorella in Australia's Great Barrier Reef Region using a low-energy process, then keeps the algae wet rather than drying it, a method the company says drives the roughly tenfold cost reduction over dried livestock feed alternatives.

Regeneron Sued Over Failed Melanoma Trial, $11B Market Cap Loss

Image
Regeneron Sued Over Failed Melanoma Trial, $11B Market Cap Loss

San Francisco – September 11, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between September 11, 2026, and September 11, 2026, with a lead plaintiff deadline set for September 11, 2026.

Regeneron's Fianlimab-Libtayo combination failed to hit its primary endpoint

The complaint centers on Regeneron's Phase 3 trial testing Fianlimab combined with Libtayo as a first-line treatment for metastatic or locally advanced melanoma, a therapy management repeatedly called a "potential blockbuster." On September 11, 2026, Regeneron disclosed the trial did not reach statistical significance on its primary endpoint of progression-free survival.

Capricor Investors Face Sept. 28 Deadline as FDA Delays Deramiocel Ruling

Image
Capricor Investors Face Sept. 28 Deadline as FDA Delays Deramiocel Ruling

San Francisco – September 11, 2026 -- Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have until September 11, 2026, to seek lead plaintiff status in a securities class action tied to the company's Duchenne muscular dystrophy therapy, deramiocel, as the FDA extends its review timeline.

FDA pushes deramiocel decision to September 11, 2026

On September 11, 2026, Capricor disclosed that the FDA extended the PDUFA target action date for its lead cell therapy deramiocel from September 11, 2026, to September 11, 2026. The agency classified the company's post-Advisory Committee submission as a major amendment, which included 24-month open-label extension data from the Phase 3 HOPE-3 study and a bid to narrow the therapy's indication to upper limb function.

Stem Cells Market to Hit $32.57B by 2031, Wissen Research Says

Image
Stem Cells Market to Hit $32.57B by 2031, Wissen Research Says

Sheridan, Wyo. – September 11, 2026 -- The global stem cells market is projected to expand from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, growing at a compound annual rate of 11.5%, according to a new study by Wissen Research.

Manufacturing gains, not new discoveries, drive the current growth phase

Analysts say the market's momentum stems largely from improvements in how cells are harvested, cultured, isolated, expanded and cryogenically preserved, rather than from newly identified therapeutic uses. Induced pluripotent stem cells (iPSCs) are drawing particular attention because they can be generated from adult tissue, avoiding sourcing and ethical issues tied to embryonic cells. Allogeneic, donor-derived therapies are also gaining share because they allow bulk, off-the-shelf manufacturing instead of custom batches per patient.

124 Trainees Join RHÖN-KLINIKUM Campus Bad Neustadt Workforce

Image
124 Trainees Join RHÖN-KLINIKUM Campus Bad Neustadt Workforce

Bad Neustadt a. d. Saale – September 11, 2026 -- RHÖN-KLINIKUM Campus Bad Neustadt has enrolled 124 new trainees across nine healthcare and administrative professions, reinforcing staffing for a facility that treats more than 160,000 patients annually with roughly 3,000 employees.

Nursing intake dominates the 2024 cohort with 52 new trainees

The largest group consists of 25 aspiring nursing specialists and 27 nursing care assistants. Occupational therapy and physiotherapy each add 22 trainees, while ten students begin training as surgical technology assistants and four as anesthesia technology assistants.

Lab Glassware Market to Hit $9.17B by 2031 as Plasticware Surges

Image
Lab Glassware Market to Hit $9.17B by 2031 as Plasticware Surges

Delray Beach, Fla. – – September 11, 2026 -- The global laboratory glassware market is projected to grow from USD 7,630 million in 2026 to USD 9,170 million by 2031, a compound annual growth rate of 4.0%, according to new data from MarketsandMarkets.

Plasticware commands 68% of market share as labs shift away from traditional glass

Plasticware, which includes pipettes, beakers, racks, bottles and containers, accounted for 68% of the laboratory glassware market in 2025. Within this segment, polyethylene products are forecast to post the fastest growth rate in the category, at 4.5% CAGR between 2026 and 2031. The shift reflects laboratory demand for lightweight, shatter-resistant, single-use consumables that improve contamination control and reduce costs across pharmaceutical, biotechnology, contract research organization and food & beverage labs.

German Hospital Chief Physician Earns European Emergency Medicine Credential

Image
German Hospital Chief Physician Earns European Emergency Medicine Credential

Frankfurt (Oder) – September 10, 2026 -- Dr. Dominik Treffer, chief physician of the Clinic for Acute and Emergency Medicine at Klinikum Frankfurt (Oder) since June 2026, has passed the examination for the European Specialist in Emergency Medicine, adding an internationally recognized credential to his qualifications as a specialist in anesthesiology with additional certifications in emergency medicine and clinical acute and emergency medicine.

Germany still lacks a standalone emergency medicine specialty recognized across many European countries

Unlike numerous European countries with an independent emergency medicine specialty, Germany has no equivalent formal credential. Care for acutely ill and injured patients in the country's central emergency departments is currently handled by physicians from a range of different medical specialties, making structured additional qualification in clinical emergency medicine increasingly significant.

Beta Bionics Faces Class Action Over iLet Insulin Pump Disclosures

Image
Beta Bionics Faces Class Action Over iLet Insulin Pump Disclosures

San Diego – September 10, 2026 -- Robbins LLP has filed a securities class action against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026, alleging the company misrepresented the safety and commercial viability of its iLet Bionic Pancreas insulin pump.

FDA warning letter contradicts prior company statements on device complaints

The complaint alleges that in October 2025, Beta Bionics disclosed an FDA Form 483 but told investors the issue was limited to complaint-reporting classification, not device safety, and that only minor customer complaints needed backfiling. Plaintiffs allege the FDA had in fact identified device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with complaints numbering in the thousands and hundreds involving life-threatening incidents requiring medical intervention.